Cargando...
Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
BACKGROUND: Docetaxel was used to treat metastatic CRPC patients. However, Doc resistance in prostate cancer (PCa) hinders its clinical application. OBJECTIVE: To understand the underlying mechanisms by which Doc resistance is developed and to find novel therapeutic target to cure Doc resistant PCa...
Guardado en:
| Publicado en: | BMC Cancer |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6324167/ https://ncbi.nlm.nih.gov/pubmed/30621625 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-5228-2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|